Helicobacter pylori infection
Conditions
Interventions
Group A1 ( Indication Group):Standard quadruple therapy
Group A2 (Non-Indication Group):Standard quadruple therapy
Group B1 (Indication Group):Traditional Chinese medicine decoction
Group B1 (Non-Indication Group):Traditional Chinese medicine decoction
Group C1 (Indication group):Traditional Chinese medicine decoction + Standard quadruple therapy
Group C2(Non-indication group):Traditional Chinese medicine decoction + Standard quadruple therapy
Group D1 (Indication group):Jin's three-needle therapy + Professor Deng Tietao's rowing exercise + Standard quadruple therapy
Group D2(Non-indication group):Jin's three-needle therapy + Professor Deng Tietao's rowing exercise + Standard quadruple therapy
Group E1 (Indication group):Jin's three-needle therapy + Professor Deng Tietao's rowing exercise+ Traditional Chinese medicine decoction.
Group E2 (Non-Indication group):Jin's three-needle therapy + Professor Deng Tietao's rowing exercise+ Traditional Chinese medicine decoction
Sponsors
The First Affiliated Hospital of Guangzhou University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1) Aged 18 to 65 (inclusive), of either gender, in good physical condition; 2) Asian race; 3) Meet the diagnostic criteria for HP infection; 4) Meet the diagnostic criteria for overweight or obesity. 5) No symptoms such as abdominal distension, abdominal pain, or burning sensation in the upper and middle abdomen in the past 3 months. 6) The patient voluntarily participates in this study, signs a written informed consent form, and is willing to cooperate with follow-up visits.
Exclusion criteria
Exclusion criteria: 1) Screen patients who have undergone eradication treatment for Helicobacter pylori infection within the previous 4 weeks; 2) Screen for individuals who have repeatedly experienced discomfort symptoms such as abdominal distension, abdominal pain, and burning sensation in the upper and middle abdomen within the previous 3 months; 3) Screen patients who have undergone any surgery within the previous 12 weeks before the examination; 4) Patients with diabetes, coagulation dysfunction, or severe skin diseases; 5) During screening, patients with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels greater than or equal to 1.5 times the upper limit of normal values specified by the center, or creatinine clearance rate (CCr) greater than the upper limit of normal values specified by the center; 6) During screening examination, the patient's total white blood cell count (WBC) is greater than 10.0X109/L or less than 1.0X109/L; 7) The patient has a history of immune deficiency diseases (such as HIV), or a history of cancer, malignant tumors, autoimmune diseases, severe cardiovascular or cerebrovascular diseases, or other diseases that may significantly reduce life expectancy; 8) History of any diseases that may affect compliance with the protocol (such as severe mental disorders, cognitive dysfunction, substance abuse, or addiction, etc.); 9) Women who are pregnant or breastfeeding, or who are capable of reproduction and unwilling/unable to adopt effective contraceptive measures; 10) Those who are known to be allergic to the ingredients contained in the medication used in this study; 11) Screen for individuals who have participated in any drug clinical trial within the previous 6 months; 12) Patients whom the researchers deem unsuitable for participation in this study;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HP eradication rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Body Mass Index;Gastrointestinal disease outcomes;Waist circumference; | — |
Countries
China
Contacts
Public ContactChang-Shaoqiong
The First Affiliated Hospital of Guangzhou University of Chinese Medicine,
Outcome results
None listed